Sort by: Helpfulness | Most Recent
2 patient evaluations for Dalfampridine (4-AP extended release) taken for the purpose of 'MS (Multiple Sclerosis)' with a side effects rating of Moderate
|Date||Dosage||Perceived effectiveness||Side Effects||Adherence||Burden|
|Jul 23, 2010||20 mg Daily||None||Moderate||Always||Not at all|
|Date||Dosage||MS (Multiple Sclerosis) Perceived effectiveness||Improve mobility Perceived effectiveness||Side Effects||Adherence||Burden|
|Jun 24, 2010||20 mg Daily||Slight||Slight Moderate||Moderate||Usually||A little|
17 additional evaluations for Dalfampridine (4-AP extended release) are not currently shared publicly.